Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 8, 2026

Inducible T7 RNA Polymerase-mediated Multigene Expression System, pMGX
10:09

Inducible T7 RNA Polymerase-mediated Multigene Expression System, pMGX

Published on: June 27, 2017

[International project--MGTX study].

Hiroaki Yoshikawa1

  • 1Health Service Center, Kanazawa University.

Rinsho Shinkeigaku = Clinical Neurology
|January 24, 2008
PubMed
Summary
This summary is machine-generated.

Extended transsternal thymectomy (ETTX) combined with prednisone offers no significant benefit over prednisone alone for myasthenia gravis patients. This study found no added advantages in weakness improvement or reduced prednisone dosage with the combined approach.

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heart rate variability versus visual analog scale for objective and subjective mental fatigue detection: A randomized controlled trial.

PLOS mental health·2026
Same author

Association between decreased taurine levels in the anterior cingulate cortex and restricted and repetitive behaviors in autism spectrum disorder: a cross-sectional study.

Frontiers in psychiatry·2025
Same author

Comparative study of Japanese nationwide epidemiological studies of myasthenia gravis using datasets of 2006 and 2018.

PloS one·2025
Same author

Associations of demyelination in the right middle temporal gyrus and right praecuneus with visuospatial cognitive dysfunction in Alzheimer's disease.

Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society·2024
Same author

Association of adverse childhood experiences and cortical neurite density alterations with posttraumatic stress disorder symptoms in autism spectrum disorder.

Frontiers in psychiatry·2023
Same author

Immunotherapy for ocular myasthenia gravis: an observational study in Japan.

Therapeutic advances in neurological disorders·2023

Area of Science:

  • Neurology
  • Surgical Research
  • Clinical Trials

Background:

  • Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
  • Prednisone is a common treatment for MG, but it has significant side effects.
  • Extended transsternal thymectomy (ETTX) is a surgical option for MG patients.

Purpose of the Study:

  • To determine if extended transsternal thymectomy (ETTX) provides additional benefits when combined with the prednisone protocol for myasthenia gravis (MG) patients.
  • To compare the efficacy of ETTX plus prednisone versus prednisone alone in improving myasthenic weakness.
  • To assess the impact of ETTX on prednisone dosage and associated toxic effects, as well as overall quality of life.

Main Methods:

  • A multi-center, international, single-blinded, randomized trial (MGTX Study) was conducted.

Related Experiment Videos

Last Updated: Jul 8, 2026

Inducible T7 RNA Polymerase-mediated Multigene Expression System, pMGX
10:09

Inducible T7 RNA Polymerase-mediated Multigene Expression System, pMGX

Published on: June 27, 2017

  • Patients received either prednisone alone or prednisone plus ETTX.
  • Outcomes were measured over 3 years using the Area Under the Quantitative Myasthenia Gravis (QMG) Weakness Score (AUQMG) and the Area Under the Prednisone Dose Time Curve (AUDTC).

    • Main Results:

    • The study is designed to compare clinical response and prednisone dosage between the two treatment groups.
    • Primary outcome measures include changes in the AUQMG score and the AUDTC.

    Conclusions:

    • The MGTX study aims to provide evidence-based recommendations for the treatment of myasthenia gravis.
    • Findings will inform clinical decisions regarding the addition of ETTX to prednisone therapy.